CTLA-4 inhibitors are more associated with colitis, rash, hepatitis, and hypophysitis, while LAG-3 inhibitors are more often associated with colitis, hepatitis, rash, endocrinopathy, and neuropathy [5,8,9,10]. Here, LAG3 is linked to colitis.